JQ1 directly represses the promoter activities of BRCA1 and RAD51

Slides:

Advertisements

Similar presentations

A B C D Rao et al., 2012; Supplementary Figure S1 p = 0.03 p = NS

Advertisements

Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.

Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.

Fig. 1. Generation of ERY974. Generation of ERY974. (A) Schematic illustration of ERY974 structure and the introduced mutations. The two Fab arms share.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Dual-Luciferase Activation Assay with Potential Targets of ZmbZIP22.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

A FOXO3a-BIM cascade mediates sensitivity to PARP and MEK inhibition

BET inhibition and depletion repress the expression of BRCA1 and RAD51

Fig. 2. Pharmacologic inhibition of ALK impairs STING activation.

Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.

Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.

Fig. 4. Biomechanical properties of treated tibiae.

Fig. 1. Schematic representation of the MANO method.

Analysis of brain and spinal cord of treated Gaa−/− mice and controls

Fig. 1. PARPi and MEKi induce inverse adaptive responses.

Fig. 3. BET inhibition reduces homologous recombination.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 3. A circadian rhythm in fibroblast wound-healing response.

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 2. GPC3 expression in normal and tumor tissues.

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Fig. 6. PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific CTL immunity in vitro. PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific.

Fig. 6. Effects of CD31-NP targeting in perfused human kidneys.

Fig. 1. Working principle of the plasmon sensor chip (NPS) for tEVs.

Fig. 6. HERV-K activation by TDP-43 and identification of binding sites on LTR. (A and B) Stem cell–derived neurons were transfected with either pcDNA.

C-MYC induces the transcription of LIG3 and PARP1 in FLT3/ITD- and BCR-ABL1–positive cells. c-MYC induces the transcription of LIG3 and PARP1 in FLT3/ITD-

Fig. 6. A circadian rhythm in keratinocyte wound healing and a diurnal variation in human burn healing outcome. A circadian rhythm in keratinocyte wound.

Fig. 4. MATE1 transcription in RCC.

Fig. 6. Safety assessment in cynomolgus monkey.

Fig. 6. Apoptotic MSCs exert in vivo immunosuppression in a TH2-type inflammation model in the absence of cytotoxic cells. Apoptotic MSCs exert in vivo.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 4. Actin polymerization rhythms are required for circadian regulation of adhesion and wound-healing efficacy by fibroblasts. Actin polymerization.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 4 DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft tumor models. DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft.

Antiproliferative effects of JQ-EZ-05 on VHL−/− ccRCC are on-target

Fig. 1. mGlu7 expression is reduced in RTT autopsy samples.

Fig. 3. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation.

Fig. 2. Resistance to S63845-induced apoptosis through loss of BAK or elevated BCL-XL. Resistance to S63845-induced apoptosis through loss of BAK or elevated.

Workflow of a sample-to-answer AST performed in less than 30 min

Fig. 1. Drug combination screen identifies BETi as acting synergistically with PARPi. Drug combination screen identifies BETi as acting synergistically.

Fig. 2 Fas controls IL-1RA–sEV secretion in murine MSCs.

Fig. 2 Analysis of CLL lymph nodes.

Fig. 3. TKI sensitivity assessed by the MANO method.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections.

Fig. 2. CD31 provides robust NP targeting in vitro but slow kinetics.

Bexarotene is neuroprotective in mouse and human HD neurons in vitro

Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets.

IIV induces CD21hiCD27+ and CD21loCD27+ influenza-specific B cells

Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation.

Fig. 2. Cellular response to FolamiRs in vitro.

Fig. 1. Specificity of FolamiR uptake in cancer cells in culture.

Fig. 5 Wireless, full-body pressure mapping on a human subject in a hospital bed. Wireless, full-body pressure mapping on a human subject in a hospital.

Fig. 2. BET inhibition enhances PARPi-induced DNA damage.

Fig. 7 Transient immunosuppression (4 weeks) supports long-term graft survival and is associated with progressive decrease in spinal regional inflammatory.

The SIM domain of RAD51 is required for HR

Fig. 3. BET inhibition reduces homologous recombination.

A and B, mRNA expression for ZNF423 (A) and BRCA1 (B) for lymphoblastoid cell lines with WT/WT (8 cell lines), WT/V (7 cell lines), and V/V (8 cell lines)

CD151-knockdown cells show an aberrant spreading response to PMA

PELP1 regulates the expression and activities of MMPs in ER-negative cells. PELP1 regulates the expression and activities of MMPs in ER-negative cells.

Dose-dependent repression of BORIS promoter activity by DNA methylation. Dose-dependent repression of BORIS promoter activity by DNA methylation. The BORIS.

Pirh2 represses p73-dependent transactivation.

Fig. 6 The C9ORF72/SMCR8 complex regulates ULK1.

Fig. 7. JQ1 represses the enhancer-promoter interaction of BRCA1.

Fig. 2. Cellular response to FolamiRs in vitro.

Presentation transcript:

Fig. 6. JQ1 directly represses the promoter activities of BRCA1 and RAD51. JQ1 directly represses the promoter activities of BRCA1 and RAD51. (A and B) BRD2/3/4 binding pattern in the BRCA1 (A) or RAD51 (B) promoter regions in VCaP cells treated with DMSO or JQ1. Bottom: Illustrations of BRCA1 promoter–luciferase (Luc) (A) and RAD51 promoter–Luc (B) reporters, in which BRCA1 or RAD51 promoter containing the BRD2/3/4 binding region was cloned into pGL3. (C and D) Quantification of the amount of BRCA1 (C) or RAD51 (D) promoter bound to BRD2/3/4 in MDA-MB-231 cells treated with DMSO or JQ1. Statistical analysis by Student’s t test, *P < 0.05; n = 3. Error bars represent means ± SD. IgG, immunoglobulin G. (E and F) Luciferase reporter assay of the activities of the BRCA1 (E) and RAD51 (F) core promoter reporters in MDA-MB-231, OVCAR10, and VCaP cells treated with DMSO, JQ1, olaparib, or JQ1 combined with olaparib. Statistical analysis by Student’s t test, *P < 0.05; n = 3. Error bars represent means ± SD. (G and H) Luciferase reporter assay of the activities of the BRCA1 (G) and RAD51 (H) core promoter reporters in MDA-MB-231, OVCAR10, and VCaP cells treated with individual siRNAs targeting BRD2/3/4 or pooled siRNAs. Statistical analysis by Student’s t test, *P < 0.05; n = 3. Error bars represent means ± SD. Lu Yang et al., Sci Transl Med 2017;9:eaal1645 Published by AAAS